Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations

Charles H. Vite, Ping Wang, Reema T. Patel, Raquel M. Walton, Steven U. Walkley, Rani S. Sellers, N. Matthew Ellinwood, Alphonsus S. Cheng, Joleen T. White, Charles A. O'Neill, Mark Haskins

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The storage disorder mucopolysaccharidosis type I (MPS I) is caused by a deficiency in lysosomal α-l-iduronidase activity. The inability to degrade glycosaminoglycans (GAG) results in lysosomal accumulation and widespread tissue lesions. Many symptoms of MPS I are amenable to treatment with recombinant human α-l-iduronidase (rhIDU), however, peripherally administered rhIDU does not cross the blood-brain barrier and has no beneficial effects in the central nervous system (CNS). A feline model of MPS I was used to evaluate the CNS effects of rhIDU following repeated intrathecal (IT) administration. Twelve animals were randomized into four groups based on the time of euthanasia and tissue evaluation following three repeat IT administrations of 0.1. mg/kg rhIDU or placebo on Study Days 1, 4 or 5, and 9. Two days after the final IT injection, the mean tissue α-l-iduronidase (IDU) activity in the brains of the two treated animals were approximately 3-times higher (50.1 and 54.9. U/mg protein) than the activity found in normal cat brains (mean of 18.3. U/mg), and remained higher than untreated MPSI brain at 1. month (2.4 and 4.1. U/mg protein) before returning to near-baseline levels after 2. months. This activity corresponded with decreased brain GAG concentrations after 2. days (1.4 and 2.0 μg/mg) and 1. month (0.9 and 1.1 μg/mg) which approached levels observed in normal animals (0.7 μg/mg). Attenuation of GAG, gangliosides GM2 and GM3, and cholesterol reaccumulation was identified at both two days and one month following final IT injection. No adverse effects attributable to IT rhIDU administration were observed. IT rhIDU may be an effective means for providing enzyme replacement therapy for the central manifestations of MPS I.

Original languageEnglish (US)
Pages (from-to)268-274
Number of pages7
JournalMolecular Genetics and Metabolism
Volume103
Issue number3
DOIs
StatePublished - Jul 2011

Fingerprint

Iduronidase
Pharmacodynamics
Mucopolysaccharidosis I
Cats
Brain
Glycosaminoglycans
Spinal Injections
Animals
Neurology
Tissue
Central Nervous System
G(M2) Ganglioside
G(M3) Ganglioside
Enzyme Replacement Therapy
Euthanasia
Felidae
Blood-Brain Barrier
Proteins
Cholesterol
Placebos

Keywords

  • Alpha-l-iduronidase
  • Enzyme replacement therapy
  • Feline
  • Intrathecal
  • Lysosomal storage disease
  • Mucopolysaccharidosis

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. / Vite, Charles H.; Wang, Ping; Patel, Reema T.; Walton, Raquel M.; Walkley, Steven U.; Sellers, Rani S.; Ellinwood, N. Matthew; Cheng, Alphonsus S.; White, Joleen T.; O'Neill, Charles A.; Haskins, Mark.

In: Molecular Genetics and Metabolism, Vol. 103, No. 3, 07.2011, p. 268-274.

Research output: Contribution to journalArticle

Vite, Charles H. ; Wang, Ping ; Patel, Reema T. ; Walton, Raquel M. ; Walkley, Steven U. ; Sellers, Rani S. ; Ellinwood, N. Matthew ; Cheng, Alphonsus S. ; White, Joleen T. ; O'Neill, Charles A. ; Haskins, Mark. / Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. In: Molecular Genetics and Metabolism. 2011 ; Vol. 103, No. 3. pp. 268-274.
@article{0a31c880025b48e1ab30e4e7f9cd68d2,
title = "Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations",
abstract = "The storage disorder mucopolysaccharidosis type I (MPS I) is caused by a deficiency in lysosomal α-l-iduronidase activity. The inability to degrade glycosaminoglycans (GAG) results in lysosomal accumulation and widespread tissue lesions. Many symptoms of MPS I are amenable to treatment with recombinant human α-l-iduronidase (rhIDU), however, peripherally administered rhIDU does not cross the blood-brain barrier and has no beneficial effects in the central nervous system (CNS). A feline model of MPS I was used to evaluate the CNS effects of rhIDU following repeated intrathecal (IT) administration. Twelve animals were randomized into four groups based on the time of euthanasia and tissue evaluation following three repeat IT administrations of 0.1. mg/kg rhIDU or placebo on Study Days 1, 4 or 5, and 9. Two days after the final IT injection, the mean tissue α-l-iduronidase (IDU) activity in the brains of the two treated animals were approximately 3-times higher (50.1 and 54.9. U/mg protein) than the activity found in normal cat brains (mean of 18.3. U/mg), and remained higher than untreated MPSI brain at 1. month (2.4 and 4.1. U/mg protein) before returning to near-baseline levels after 2. months. This activity corresponded with decreased brain GAG concentrations after 2. days (1.4 and 2.0 μg/mg) and 1. month (0.9 and 1.1 μg/mg) which approached levels observed in normal animals (0.7 μg/mg). Attenuation of GAG, gangliosides GM2 and GM3, and cholesterol reaccumulation was identified at both two days and one month following final IT injection. No adverse effects attributable to IT rhIDU administration were observed. IT rhIDU may be an effective means for providing enzyme replacement therapy for the central manifestations of MPS I.",
keywords = "Alpha-l-iduronidase, Enzyme replacement therapy, Feline, Intrathecal, Lysosomal storage disease, Mucopolysaccharidosis",
author = "Vite, {Charles H.} and Ping Wang and Patel, {Reema T.} and Walton, {Raquel M.} and Walkley, {Steven U.} and Sellers, {Rani S.} and Ellinwood, {N. Matthew} and Cheng, {Alphonsus S.} and White, {Joleen T.} and O'Neill, {Charles A.} and Mark Haskins",
year = "2011",
month = "7",
doi = "10.1016/j.ymgme.2011.03.011",
language = "English (US)",
volume = "103",
pages = "268--274",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations

AU - Vite, Charles H.

AU - Wang, Ping

AU - Patel, Reema T.

AU - Walton, Raquel M.

AU - Walkley, Steven U.

AU - Sellers, Rani S.

AU - Ellinwood, N. Matthew

AU - Cheng, Alphonsus S.

AU - White, Joleen T.

AU - O'Neill, Charles A.

AU - Haskins, Mark

PY - 2011/7

Y1 - 2011/7

N2 - The storage disorder mucopolysaccharidosis type I (MPS I) is caused by a deficiency in lysosomal α-l-iduronidase activity. The inability to degrade glycosaminoglycans (GAG) results in lysosomal accumulation and widespread tissue lesions. Many symptoms of MPS I are amenable to treatment with recombinant human α-l-iduronidase (rhIDU), however, peripherally administered rhIDU does not cross the blood-brain barrier and has no beneficial effects in the central nervous system (CNS). A feline model of MPS I was used to evaluate the CNS effects of rhIDU following repeated intrathecal (IT) administration. Twelve animals were randomized into four groups based on the time of euthanasia and tissue evaluation following three repeat IT administrations of 0.1. mg/kg rhIDU or placebo on Study Days 1, 4 or 5, and 9. Two days after the final IT injection, the mean tissue α-l-iduronidase (IDU) activity in the brains of the two treated animals were approximately 3-times higher (50.1 and 54.9. U/mg protein) than the activity found in normal cat brains (mean of 18.3. U/mg), and remained higher than untreated MPSI brain at 1. month (2.4 and 4.1. U/mg protein) before returning to near-baseline levels after 2. months. This activity corresponded with decreased brain GAG concentrations after 2. days (1.4 and 2.0 μg/mg) and 1. month (0.9 and 1.1 μg/mg) which approached levels observed in normal animals (0.7 μg/mg). Attenuation of GAG, gangliosides GM2 and GM3, and cholesterol reaccumulation was identified at both two days and one month following final IT injection. No adverse effects attributable to IT rhIDU administration were observed. IT rhIDU may be an effective means for providing enzyme replacement therapy for the central manifestations of MPS I.

AB - The storage disorder mucopolysaccharidosis type I (MPS I) is caused by a deficiency in lysosomal α-l-iduronidase activity. The inability to degrade glycosaminoglycans (GAG) results in lysosomal accumulation and widespread tissue lesions. Many symptoms of MPS I are amenable to treatment with recombinant human α-l-iduronidase (rhIDU), however, peripherally administered rhIDU does not cross the blood-brain barrier and has no beneficial effects in the central nervous system (CNS). A feline model of MPS I was used to evaluate the CNS effects of rhIDU following repeated intrathecal (IT) administration. Twelve animals were randomized into four groups based on the time of euthanasia and tissue evaluation following three repeat IT administrations of 0.1. mg/kg rhIDU or placebo on Study Days 1, 4 or 5, and 9. Two days after the final IT injection, the mean tissue α-l-iduronidase (IDU) activity in the brains of the two treated animals were approximately 3-times higher (50.1 and 54.9. U/mg protein) than the activity found in normal cat brains (mean of 18.3. U/mg), and remained higher than untreated MPSI brain at 1. month (2.4 and 4.1. U/mg protein) before returning to near-baseline levels after 2. months. This activity corresponded with decreased brain GAG concentrations after 2. days (1.4 and 2.0 μg/mg) and 1. month (0.9 and 1.1 μg/mg) which approached levels observed in normal animals (0.7 μg/mg). Attenuation of GAG, gangliosides GM2 and GM3, and cholesterol reaccumulation was identified at both two days and one month following final IT injection. No adverse effects attributable to IT rhIDU administration were observed. IT rhIDU may be an effective means for providing enzyme replacement therapy for the central manifestations of MPS I.

KW - Alpha-l-iduronidase

KW - Enzyme replacement therapy

KW - Feline

KW - Intrathecal

KW - Lysosomal storage disease

KW - Mucopolysaccharidosis

UR - http://www.scopus.com/inward/record.url?scp=79958064659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958064659&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2011.03.011

DO - 10.1016/j.ymgme.2011.03.011

M3 - Article

VL - 103

SP - 268

EP - 274

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 3

ER -